Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of treatment failure in efficacy trials of drugs against Plasmodium vivax by genotyping neutral and drug resistance-associated markers.

Antimicrobial agents and chemotherapy - 1 Sept 2011

Barnadas Celine, Koepfli Cristian, Karunajeewa Harin A, Siba Peter M, Davis Timothy M E, Mueller Ivo

Abstract excerpt

Plasmodium vivax intervention trials customarily report uncorrected treatment failure rates. Application of recrudescence-reinfection genotyping and drug resistance single-nucleotide polymorphism typing to a 4-arm comparative efficacy trial illustrated that molecular approaches can assist in understanding the relative contributions of true drug resistance (recurrent with same genotype) and new infections to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimalarials
Share to Drug Resistance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Kaplan-Meier Estimate

Share to Plasmodium vivax

Share to Polymerase Chain Reaction

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 21709097
DOI: 10.1128/AAC.01552-10
PMCID: PMC3165340

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of treatment failure in efficacy trials of drugs against Plasmodium vivax by genotyping neutral and drug resistance-associated markers.PMID 21709097Read ↗

Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax.Semantic proximity Read ↗

Molecular genotyping to distinguish between recrudescents and new infections in treatment trials of Plasmodium falciparum malaria conducted in Sub-Saharan Africa: adjustment of parasitological outcomes and assessment of genotyping effectiveness.Semantic proximity Read ↗

Revisiting <i>Plasmodium vivax</i> molecular correctionSemantic proximity Read ↗

Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.Semantic proximity Read ↗

The molecular basis of antimalarial drug resistance in Plasmodium vivaxSemantic proximity Read ↗

Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria.Semantic proximity Read ↗

Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directionsSemantic proximity Read ↗

Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria.Semantic proximity Read ↗

Preventing antimalarial drug resistance with triple artemisinin-based combination therapiesSemantic proximity Read ↗

Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy.Semantic proximity Read ↗

The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995-2005.Semantic proximity Read ↗

In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.